Journal of the American Medical Association (JAMA) SurgeryTranexamic acid is an antifibrinolytic compound which inhibits fibrinolysis by blocking the binding of plasminogen and plasmin to fibrin, thus preventing dissolution of the haemostatic plug. TAKE-HOME MESSAGE Question Is intravenous administration of tranexamic acid associated wi...

The New England Journal of Medicine: Postpartum hemorrhage remains a leading cause of severe maternal complications and death worldwide. Prophylactic administration of an uterotonic agent is recommended to reduce the risk of postpartum hemorrhage. Tranexamic acid has emerged in the past decade as another candidate drug to prevent blood l...

A meta-analysis of the randomized controlled trials: The American Journal of Emergency Medicine Trauma remains a leading cause of death worldwide, and the management of injured patients at risk for hemorrhage has evolved over time. Interventions provided to injured patients during prehospital care, close to the time of injury, result...

Trauma is the leading cause of death and disability worldwide. In both military and civilian settings, hemorrhage remains the most common cause of preventable death after traumatic injury. In recent years, there has been considerable interest in antifibrinolytic agents for the prevention of hemorrhagic death in severe trauma patients. T...

The American College of Cardiology (ACC) & The New England Journal of Medicine (NEJM): Key Prescribing Notes: Perioperative bleeding is common complications in patients undergoing noncardiac surgery, is associated with increased morbidity and mortality. The goal of the POISE-3 trial was to determine whether tranexamic acid, when u...